ARS Pharmaceuticals
SPRY
76 hedge funds and large institutions have $864M invested in ARS Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 10 closing their positions.
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
12% more funds holding
Funds holding: 68 → 76 (+8)
0.58% more ownership
Funds ownership: 79.6% → 80.18% (+0.58%)
28% less capital invested
Capital invested by funds: $1.21B → $864M (-$341M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$12.2M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$8.79M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$6.3M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$5.48M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$4.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$10.9M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.37M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.45M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.41M |
| 5 |
VA
VR Adviser
New York
|
-$3.71M |
SPRY Hedge Fund Activity: Q2 2021 in Review
76 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q2 2021, worth a combined $864M — down 28% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SPRY positions and 10 closed out — a net gain of 8 holders — while 25 added to existing stakes and 19 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $12.2M. The largest seller was BlackRock, cutting an estimated $10.9M.
- 76 institutional investors held ARS Pharmaceuticals (SPRY) as of Q2 2021, up from 68 in Q1 2021.
- Funds reported $864M of ARS Pharmaceuticals stock for Q2 2021, down 28% quarter-over-quarter.
- 18 funds opened new ARS Pharmaceuticals positions in Q2 2021 and 10 closed out, a net change of +8 holders.
- The largest ARS Pharmaceuticals buyer in Q2 2021 was Wasatch Advisors, an estimated $12.2M added.
- The largest ARS Pharmaceuticals seller in Q2 2021 was BlackRock, an estimated $10.9M sold.
Based on aggregated 13F filings for Q2 2021.